Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants

IMPORTANCE Intravitreal bevacizumab effectively treats severe retinopathy of prematurity (ROP), but it enters the bloodstream and may reduce serum vascular endothelial growth factor (VEGF), potentially causing detrimental effects on developing organs in the premature infant. OBJECTIVE To evaluate the association of intravitreal bevacizumab with plasma bevacizumab and VEGF concentrations at 2 and 4 weeks after predefined, de-escalating doses of intravitreal bevacizumab were administered to infants with severe ROP. DESIGN, SETTING, AND PARTICIPANTS This phase 1 dose de-escalation case series studywas conducted at 10 US hospitals of ophthalmology institutions from May 21, 2015, toMay 7, 2019. Blood samples were collected 2 and 4 weeks after intravitreal bevacizumab injection. Participants included 83 premature infants with type 1 ROP in 1 or both eyes and no previous ROP treatment. Data were analyzed from April 2017 to August 2021. INTERVENTIONS Study eyes received a single bevacizumab injection of 0.250mg, 0.125mg, 0.063mg, 0.031mg, 0.016mg, 0.008mg, 0.004mg, or 0.002mg. When the fellow eye required treatment, one dose higher was administered. Total dose administered at baseline was defined as the sum of doses given to each eye within 3 days of initial study-eye injection. MAIN OUTCOMES AND MEASURES Plasma bevacizumab concentration at 2 and 4weeks after injection and the percentage change in plasma VEGF concentrations from pretreatment levels. RESULTS A total of 83 infants (mean [SD] age, 25 [2] weeks; 48 boys [58%]) were included in this study. Higher doses of bevacizumab administered at baseline were associated with higher plasma bevacizumab concentrations at 2 weeks (rho, 0.53; 95% CI, 0.31-0.70) and 4 weeks (rho, 0.44; 95% CI, 0.18-0.64). Plasma VEGF concentrations decreased by 50% or more from pretreatment levels in 40 of 66 infants (61%) at 2 weeks and 31 of 61 infants (51%) at 4 weeks, but no association was observed between the total dose of bevacizumab administered at baseline and percentage change in plasma VEGF concentrations 2 weeks (rho, -0.04; 95% CI, -0.28 to 0.20) or 4 weeks (rho, -0.17; 95% CI, -0.41 to 0.08) after injection. CONCLUSIONS AND RELEVANCE Results of this phase 1 dose de-escalation case series study revealed that bevacizumab doses as low as 0.002mg were associated with reduced plasma VEGF levels for most infants at 2 and 4 weeks after intravitreal administration; however, no association was observed between total bevacizumab dose administered and reductions in plasma VEGF levels from preinjection to 2 weeks or 4 weeks. Additional studies are needed to evaluate the long-term effects of low-dose bevacizumab on neurodevelopment and retinal structure.

Automated summary

The results of this phase 1 dose de-escalation case series study showed that intravitreal bevacizumab at low doses reduced plasma VEGF levels in infants with severe retinopathy of prematurity. However, there was no association between the total dose of bevacizumab administered and the reduction in plasma VEGF levels.